BRPI0410503A - uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição - Google Patents

uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição

Info

Publication number
BRPI0410503A
BRPI0410503A BRPI0410503-6A BRPI0410503A BRPI0410503A BR PI0410503 A BRPI0410503 A BR PI0410503A BR PI0410503 A BRPI0410503 A BR PI0410503A BR PI0410503 A BRPI0410503 A BR PI0410503A
Authority
BR
Brazil
Prior art keywords
composition
topical
ivermectin
manufacture
pharmaceutical composition
Prior art date
Application number
BRPI0410503-6A
Other languages
English (en)
Inventor
Vincent Manetta
Gary R Watkins
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33312271&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410503(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR0305048A external-priority patent/FR2854074B1/fr
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BRPI0410503A publication Critical patent/BRPI0410503A/pt
Publication of BRPI0410503B1 publication Critical patent/BRPI0410503B1/pt
Publication of BRPI0410503B8 publication Critical patent/BRPI0410503B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

"USO DA IVERMECTINA PARA A FABRICAçãO DE UMA COMPOSIçãO FARMACêUTICA TóPICA, COMPOSIçãO TóPICA E USO DA COMPOSIçãO". A presente invenção trata do uso da ivermectina para a fabricação de uma composição farmacêutica tópica destinada ao tratamento da rosácea. Ela trata também de uma composição farmacêutica tópica destinada ao uso humano que compreende ivermectina.
BRPI0410503A 2003-04-24 2004-04-22 composição tópica e uso da composição BRPI0410503B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR03/05048 2003-04-24
FR0305048A FR2854074B1 (fr) 2003-04-24 2003-04-24 Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
US46899403P 2003-05-09 2003-05-09
US60/468,994 2003-05-09
PCT/EP2004/004950 WO2004093886A1 (en) 2003-04-24 2004-04-22 Topical formulation of ivermectin for the treatment of dermatological conditions

Publications (3)

Publication Number Publication Date
BRPI0410503A true BRPI0410503A (pt) 2006-06-20
BRPI0410503B1 BRPI0410503B1 (pt) 2018-07-10
BRPI0410503B8 BRPI0410503B8 (pt) 2021-05-25

Family

ID=33312271

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410503A BRPI0410503B8 (pt) 2003-04-24 2004-04-22 composição tópica e uso da composição

Country Status (16)

Country Link
US (6) US7550440B2 (pt)
EP (1) EP1620113B1 (pt)
JP (2) JP5711867B2 (pt)
KR (1) KR101187231B1 (pt)
AU (1) AU2004231323C1 (pt)
BR (1) BRPI0410503B8 (pt)
CA (1) CA2522579C (pt)
CY (2) CY1111797T1 (pt)
FR (1) FR15C0069I2 (pt)
HU (1) HUS1500048I1 (pt)
LT (1) LTC1620113I2 (pt)
LU (1) LU92915I2 (pt)
MX (1) MXPA05011208A (pt)
PL (2) PL378932A1 (pt)
RU (1) RU2350333C3 (pt)
WO (1) WO2004093886A1 (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2854074B1 (fr) 2003-04-24 2007-11-23 Galderma Res & Dev Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
US7648711B2 (en) * 2003-05-25 2010-01-19 Yuwan Wang Dimethicone-containing sustained release injection formulation
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) * 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine
FR2883181B1 (fr) 2005-03-17 2007-05-18 Galderma Sa Composition a base d'une avermectine et d'acide azelaique notamment pour le traitement de la rosacee
FR2886852B1 (fr) * 2005-06-10 2007-11-23 Galderma Sa Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
FR2886851B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
FR2886850B1 (fr) * 2005-06-10 2007-10-05 Galderma Sa Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
FR2894823B1 (fr) 2005-12-20 2008-02-29 Galderma Sa Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie
FR2900052B1 (fr) * 2006-04-19 2011-02-18 Galderma Sa Composition comprenant au moins une phase aqueuse et au moins une phase grasse comprenant de l'ivermectine
FR2906468B1 (fr) * 2006-09-28 2012-09-21 Galderma Sa Utilisation de composes de la famille des avermectines pour le traitement de desordres dermatologiques
FR2907013B1 (fr) * 2006-10-12 2012-09-21 Galderma Sa Produits de soin cutane a double compartiment comprenant de l'ivermectine, et leurs utilisations
FR2907012B1 (fr) 2006-10-12 2012-09-21 Galderma Sa Composition dermatologique comprenant des nanocapsules d'avermectine, son procede de preparation et son utilisation
EP2091325B1 (en) 2006-10-12 2014-08-06 Topaz Pharmaceuticals Inc. Shampoo-conditioner formulations comprising an avermectin for elimination of, and prophylaxis against, susceptible and treatment-resistant strains of lice
US8901163B2 (en) * 2007-01-03 2014-12-02 Galderma S.A. Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound
DE102007056424A1 (de) * 2007-11-23 2009-05-28 Neopharmacie Gmbh Pharmazeutische Zusammensetzung, enthaltend eine Öl/Wasser-Emulsion
JP5694944B2 (ja) * 2008-10-29 2015-04-01 トパズ ファーマシューティカルズ インコーポレイティド エマルション系局所治療用製剤の保存方式
JP2012513387A (ja) * 2008-12-23 2012-06-14 ガルデルマ・ソシエテ・アノニム 感水性の活性成分を含む、局所用医薬組成物
ES2658897T3 (es) 2011-08-24 2018-03-12 Novan, Inc. Macromoléculas de liberación de óxido nítrico ajustables que tienen múltiples estructuras donantes de óxido nítrico
US8642665B2 (en) 2011-12-16 2014-02-04 Conopco, Inc. Environmentally friendly, low whitening compositions
JP5717034B2 (ja) * 2012-08-27 2015-05-13 丸和バイオケミカル株式会社 マクロライド系化合物を含有する土壌線虫防除用薬剤
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
CN103356687B (zh) 2012-10-19 2016-06-01 厦门大学 一种伊维菌素及其衍生物的用途
FR3003761B1 (fr) * 2013-03-29 2016-01-01 Galderma Sa Utilisation d'une lactone macrocyclique pour le traitement d'une infection par un papillomavirus
US9782425B2 (en) 2013-07-08 2017-10-10 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
WO2015079016A1 (en) 2013-11-29 2015-06-04 Galderma Sa Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis
CN104706584A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种伊维菌素脂肪乳浓缩液、其制备方法及用途
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
WO2016022066A1 (en) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
FR3026010B1 (fr) * 2014-09-18 2016-11-04 Galderma Sa Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee
WO2016096797A1 (en) 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses
WO2016096795A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family for treating and/or preventing inflammatory dermatoses
EP3362045B1 (en) 2015-10-13 2019-10-09 Galderma S.A. A process for preparing a composition comprising a high concentration of one or more avermectins
WO2017064205A1 (en) 2015-10-13 2017-04-20 Galderma Sa A process for preparing a stable emulsion comprising one or more avermectins
EP3493795A1 (en) 2016-08-04 2019-06-12 Nestlé Skin Health SA Compositions and the use thereof for treating or preventing rosacea
US11160780B2 (en) * 2016-09-30 2021-11-02 Aurobindo Pharma Ltd. Pharmaceutical composition of ivermectin and process for preparation thereof
US11234959B2 (en) 2016-11-03 2022-02-01 Galderma Holding SA Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema
EP3326614A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds
EP3326609A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without gelling agents
EP3326608A1 (en) 2016-11-24 2018-05-30 Nestlé Skin Health SA Composition comprising avermectin compounds without solid fatty substances
KR20260035292A (ko) * 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2019241498A1 (en) 2018-06-15 2019-12-19 W. R. Grace & Co.-Conn Defoamer active, manufacturing method thereof, and defoaming formuation
SG11202102783QA (en) * 2018-09-28 2021-04-29 Galderma Res & Dev Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
WO2020210784A1 (en) 2019-04-12 2020-10-15 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same
US12161752B2 (en) 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
CN115379824A (zh) * 2019-08-21 2022-11-22 生物制药股份有限公司 用于局部递送活性剂的溶剂递送系统
KR20220052474A (ko) 2020-10-21 2022-04-28 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-21-3p 및 이의 용도
KR102480430B1 (ko) 2020-10-21 2022-12-21 순천향대학교 산학협력단 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도
US11291679B1 (en) * 2021-03-22 2022-04-05 Mountain Valley Md Inc. Injectable, infusable, instillable ivermectin adjuvant for cancer therapies
EP4062907A1 (fr) 2021-03-23 2022-09-28 Substipharm Formulation par voie orale d'ivermectine et utilisations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
GB9422306D0 (en) * 1994-11-04 1994-12-21 Sandoz Ltd Organic compounds
US5952371A (en) * 1996-10-16 1999-09-14 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
RU2138268C1 (ru) * 1997-09-22 1999-09-27 Мосин Владимир Александрович Средство, подавляющее пролиферацию и вызывающее гибель опухолевых клеток, при этом защищающее нормальные клетки
US5952372A (en) * 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
US6310968B1 (en) * 1998-11-24 2001-10-30 Picker International, Inc. Source-assisted attenuation correction for emission computed tomography
IL144561A0 (en) * 1999-01-25 2002-05-23 Optime Therapeutics Inc Liposome compositions and methods for treating pests utilizing the same
US6133310A (en) * 1999-08-26 2000-10-17 Parks; L. Dean Method of treatment of rosacea
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6399652B1 (en) * 2000-06-29 2002-06-04 L. Dean Parks Method of treating acne vulgaris using avermectin compound
US6319945B1 (en) 2000-06-29 2001-11-20 L. Dean Parks Method of treatment of seborrheic dermatitis
US6399651B1 (en) 2000-06-29 2002-06-04 L. Dean Parks Method of treating dermatoses using avermectin compound
US20030064940A1 (en) * 2001-10-02 2003-04-03 Parks L. Dean Kit for treating acne vulgaris using avermectin compound
DE10063946A1 (de) * 2000-12-20 2002-07-04 Basf Ag Verwendung von Lichtschutzmittelkombinationen, die als wesentlichen Bestandteil 2,2'-p-Phenylen-bis(3,1-benzoxazin-4-on) enthalten als photostabile UV-Filter in kosmetischen und pharmazeutischen Zubereitungen
EP1476121A4 (en) * 2002-02-08 2010-10-27 Merck Sharp & Dohme TOPICAL IVERMECTIN COMPOSITION
CN1649578A (zh) * 2002-03-04 2005-08-03 戴弗根斯公司 杀线虫的脂肪酸和脂肪酸酯相关化合物
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
DE602005020912D1 (de) 2004-03-18 2010-06-10 Galderma Sa Ivermectin enthaltende creme
FR2867684B1 (fr) 2004-03-18 2006-05-05 Galderma Sa Gel creme contenant de l'ivermectine

Also Published As

Publication number Publication date
EP1620113A1 (en) 2006-02-01
CA2522579A1 (en) 2004-11-04
US7550440B2 (en) 2009-06-23
AU2004231323C1 (en) 2016-11-03
BRPI0410503B1 (pt) 2018-07-10
RU2350333C3 (ru) 2018-08-24
RU2005136438A (ru) 2006-05-27
JP2006524212A (ja) 2006-10-26
CY1111797T1 (el) 2015-10-07
PL1620113T3 (pl) 2011-10-31
JP5711867B2 (ja) 2015-05-07
FR15C0069I1 (pt) 2015-12-04
JP5538461B2 (ja) 2014-07-02
US8093219B2 (en) 2012-01-10
WO2004093886A1 (en) 2004-11-04
US20130209381A1 (en) 2013-08-15
US20090227668A1 (en) 2009-09-10
CA2522579C (en) 2012-08-28
PL378932A1 (pl) 2006-06-12
FR15C0069I2 (fr) 2016-04-22
CY2016031I1 (el) 2017-03-15
US20060100165A1 (en) 2006-05-11
AU2004231323A1 (en) 2004-11-04
US20120258062A1 (en) 2012-10-11
US8415311B2 (en) 2013-04-09
RU2350333C2 (ru) 2009-03-27
LTC1620113I2 (lt) 2018-02-26
HUS1500048I1 (hu) 2017-10-30
US20120077766A1 (en) 2012-03-29
US8598129B2 (en) 2013-12-03
KR101187231B1 (ko) 2012-10-02
LU92915I2 (fr) 2016-02-17
EP1620113B1 (en) 2011-07-13
AU2004231323B2 (en) 2009-12-10
US8470788B2 (en) 2013-06-25
BRPI0410503B8 (pt) 2021-05-25
JP2012126738A (ja) 2012-07-05
US20090252797A1 (en) 2009-10-08
KR20060004667A (ko) 2006-01-12
CY2016031I2 (el) 2017-03-15
MXPA05011208A (es) 2005-12-14
US8080530B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
DE60313597D1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
BRPI0114927B8 (pt) composição de gel farmacêutica não aquosa para aplicação na pele, e, uso de uma composição
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
BRPI0416205A (pt) uso de antibióticos como adjuvantes de vacina
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
AR109263A2 (es) Composición que comprende moxidectina
BRPI0415713A (pt) mio-inositol hexafosfato para uso tópico
ECSP034518A (es) Nuevos retinoides para el tratamiento de enfisema
BR0212576A (pt) Método para o tratamento de distúrbios da pele
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BRPI0414386A (pt) composto, métodos para fabricação do mesmo, para tratamento ou prevenção de uma doença, para ativação da função de er em uma célula óssea, para inibição de função de er em uma célula, para inibição da expressão de il-6, para inibição do crescimento de uma célula neoplásica expressando er, para prevenção de espermatogenese, para prevenção de um efeito reprodutivo adverso associados com exposição a uma falta de equilìbrio hormonal natural ou quìmica ambiental, e, composição
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0413083A (pt) métodos para tratar inflamação e doenças associadas com inflamação com uma estatina e éter
BRPI0511209A (pt) composição farmacêutica e uso de uma associação de propionato de clobetasol e de calcitriol
BRPI0408944A (pt) método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
BRPI0517826A (pt) uso de extratos vegetais para prevenir e/ou reduzir os sinais de desconforto subjetivo e/ou irritação na aplicação tópica de produtos cosméticos
PT1220676E (pt) Prevencao do cancro colorrectal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2824 DE 18/02/2025 POR TER SIDO INDEVIDA.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 22/04/2024